Display options
Cite
Gao J, Zhang W, Ehrhardt A. Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy. Cancers (Basel). 2020;12(5)doi: 10.3390/cancers12051139.
Gao, J., Zhang, W., & Ehrhardt, A. (2020). Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy. Cancers, 12(5), . https://doi.org/10.3390/cancers12051139
Gao, Jian, et al. "Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy." Cancers vol. 12,5 (2020). doi: https://doi.org/10.3390/cancers12051139
Gao J, Zhang W, Ehrhardt A. Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy. Cancers (Basel). 2020 May 02;12(5). doi: 10.3390/cancers12051139. PMID: 32370135; PMCID: PMC7281331.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 May 02;12(5). doi: 10.3390/cancers12051139.

Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy.

Cancers

Jian Gao, Wenli Zhang, Anja Ehrhardt

Affiliations

  1. Institute for Virology and Microbiology, Center for Biomedical Education and Research (ZBAF), Department of Human Medicine, Faculty of Health, Witten/Herdecke University, 58453 Witten, Germany.

PMID: 32370135 PMCID: PMC7281331 DOI: 10.3390/cancers12051139

Abstract

Adenoviral vectors (AdVs) have attracted much attention in the fields of vaccine development and treatment for diseases such as genetic disorders and cancer. In this review, we discuss the utility of AdVs in cancer therapies. In recent years, AdVs were modified as oncolytic AdVs (OAs) that possess the characteristics of cancer cell-specific replication and killing. Different carriers such as diverse cells and extracellular vesicles are being explored for delivering OAs into cancer sites after systemic administration. In addition, there are also various strategies to improve cancer-specific replication of OAs, mainly through modifying the early region 1 (E1) of the virus genome. It has been documented that oncolytic viruses (OVs) function through stimulating the immune system, resulting in the inhibition of cancer progression and, in combination with classical immune modulators, the anti-cancer effect of OAs can be even further enforced. To enhance the cancer treatment efficacy, OAs are also combined with other standard treatments, including surgery, chemotherapy and radiotherapy. Adenovirus type 5 (Ad5) has mainly been explored to develop vectors for cancer treatment with different modulations. Only a limited number of the more than 100 identified AdV types were converted into OAs and, therefore, the construction of an adenovirus library for the screening of potential novel OA candidates is essential. Here, we provide a state-of-the-art overview of currently performed and completed clinic trials with OAs and an adenovirus library, providing novel possibilities for developing innovative adenoviral vectors for cancer treatment.

Keywords: adenoviral vectors; adenovirus; adenovirus library; cancer; chemotherapy; delivery; immunotherapy; oncolytic adenovirus; radiotherapy

References

  1. Cancer Res. 1994 Dec 1;54(23):6053-6 - PubMed
  2. Cancer Res. 1999 Sep 1;59(17):4200-3 - PubMed
  3. Cell Rep. 2017 May 23;19(8):1698-1709 - PubMed
  4. J Control Release. 2018 Aug 10;283:223-234 - PubMed
  5. Int J Cancer. 2013 May 15;132(10):2327-38 - PubMed
  6. Mol Ther. 2010 Nov;18(11):1960-71 - PubMed
  7. Cancer J Sci Am. 1998 Nov-Dec;4(6):364-9 - PubMed
  8. J Immunol. 2002 May 15;168(10):4897-906 - PubMed
  9. Science. 2011 Mar 25;331(6024):1612-6 - PubMed
  10. Mol Ther. 2006 Feb;13(2):347-56 - PubMed
  11. Oncoimmunology. 2013 Aug 1;2(8):e25083 - PubMed
  12. PLoS One. 2018 Jun 27;13(6):e0199563 - PubMed
  13. J Virol. 2011 Dec;85(24):13114-23 - PubMed
  14. J Immunother Cancer. 2017 Sep 19;5(1):71 - PubMed
  15. Sci Rep. 2013;3:1812 - PubMed
  16. Hum Gene Ther. 2007 Jul;18(7):589-602 - PubMed
  17. Front Oncol. 2017 Jul 24;7:153 - PubMed
  18. J Cancer. 2017 May 12;8(8):1425-1432 - PubMed
  19. Gene Ther. 2001 Feb;8(4):308-15 - PubMed
  20. Mol Ther. 2012 Sep;20(9):1821-30 - PubMed
  21. Cytotherapy. 2013 Dec;15(12):1563-70 - PubMed
  22. Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):268-76 - PubMed
  23. Annu Rev Immunol. 2002;20:621-67 - PubMed
  24. Cancers (Basel). 2018 Jun 14;10(6): - PubMed
  25. Cancer Res. 2008 Jul 15;68(14):5778-84 - PubMed
  26. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13159-64 - PubMed
  27. Cytotherapy. 2008;10(6):625-32 - PubMed
  28. J Virol. 1998 Oct;72(10):7909-15 - PubMed
  29. J Cell Physiol. 2006 Aug;208(2):298-306 - PubMed
  30. Mol Cancer Ther. 2016 Sep;15(9):2259-69 - PubMed
  31. Oncogene. 2000 Jan 6;19(1):2-12 - PubMed
  32. Cancer Biol Ther. 2010 Nov 15;10(10):983-93 - PubMed
  33. Blood. 2007 Apr 1;109(7):2832-9 - PubMed
  34. Sci Rep. 2019 May 16;9(1):7504 - PubMed
  35. Nat Biotechnol. 2012 May;30(5):440-6 - PubMed
  36. Cancer Res. 2003 Nov 1;63(21):7497-506 - PubMed
  37. Int J Radiat Biol. 2001 Feb;77(2):185-94 - PubMed
  38. Hum Gene Ther Methods. 2018 Jun;29(3):124-134 - PubMed
  39. Mol Ther Nucleic Acids. 2019 Mar 1;14:364-376 - PubMed
  40. Int J Cancer. 2014 Mar 1;134(5):1091-101 - PubMed
  41. Hum Gene Ther. 2005 Sep;16(9):1016-27 - PubMed
  42. Blood. 2009 Feb 26;113(9):1909-18 - PubMed
  43. Nat Med. 2003 Nov;9(11):1408-12 - PubMed
  44. Semin Immunol. 2009 Oct;21(5):301-7 - PubMed
  45. Apoptosis. 2009 Apr;14(4):597-606 - PubMed
  46. Hum Mol Genet. 2001 Apr;10(7):699-703 - PubMed
  47. Nat Biotechnol. 2020 Mar 23;: - PubMed
  48. Oncogene. 1999 Jun 3;18(22):3383-90 - PubMed
  49. Cancer Gene Ther. 2011 Oct;18(10):744-50 - PubMed
  50. ESMO Open. 2019 Jun 12;4(Suppl 3):e000510 - PubMed
  51. PLoS One. 2010 Jan 27;5(1):e8916 - PubMed
  52. Clin Cancer Res. 2015 Mar 15;21(6):1321-8 - PubMed
  53. Clin Cancer Res. 1999 Dec;5(12):4224-32 - PubMed
  54. Cancer Biol Ther. 2003 Sep-Oct;2(5):511-5 - PubMed
  55. Lancet Oncol. 2017 Dec;18(12):e731-e741 - PubMed
  56. J Clin Oncol. 2009 Sep 10;27(26):4371-7 - PubMed
  57. Cancer Gene Ther. 2005 Aug;12(8):715-22 - PubMed
  58. Trends Biochem Sci. 1991 Oct;16(10):378-81 - PubMed
  59. Hum Gene Ther. 2005 Sep;16(9):1014-5 - PubMed
  60. Clin Cancer Res. 2015 Mar 1;21(5):1115-26 - PubMed
  61. Blood. 2004 Oct 15;104(8):2432-40 - PubMed
  62. Cancer Res. 2013 Aug 15;73(16):5003-15 - PubMed
  63. Br J Cancer. 2003 Aug 4;89(3):577-84 - PubMed
  64. Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):861-8 - PubMed
  65. Trends Pharmacol Sci. 2012 Aug;33(8):442-8 - PubMed
  66. Clin Cancer Res. 2007 Apr 15;13(8):2455-62 - PubMed
  67. Mol Ther. 2011 Sep;19(9):1714-26 - PubMed
  68. Nat Med. 2011 Jan;17(1):96-104 - PubMed
  69. Nat Commun. 2019 Jul 19;10(1):3236 - PubMed
  70. Cancer Gene Ther. 2003 Mar;10(3):193-200 - PubMed
  71. J Virol. 2004 Dec;78(23):13207-15 - PubMed
  72. Viruses. 2018 Oct 13;10(10): - PubMed
  73. J Immunol. 2001 Aug 1;167(3):1313-24 - PubMed
  74. Ann Oncol. 2012 Oct;23 Suppl 7:vii124-30 - PubMed
  75. J Biol Chem. 2012 Sep 21;287(39):32494-511 - PubMed
  76. Neuroendocrinology. 2017;105(1):54-66 - PubMed
  77. PLoS Pathog. 2015 Feb 12;11(2):e1004657 - PubMed
  78. Clin Cancer Res. 2001 Jan;7(1):127-35 - PubMed
  79. Sci Rep. 2020 Jan 16;10(1):425 - PubMed
  80. J Gene Med. 2004 Jun;6(6):631-41 - PubMed
  81. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3602-6 - PubMed
  82. J Immunol. 1997 Jan 15;158(2):551-9 - PubMed
  83. J Clin Oncol. 2001 Jul 1;19(13):3280-7 - PubMed
  84. Gene Ther. 2008 May;15(10):753-8 - PubMed
  85. Cancer Res. 2019 Sep 1;79(17):4503-4514 - PubMed
  86. J Immunol. 2015 Apr 1;194(7):3475-86 - PubMed
  87. Cancer Res. 2013 Jan 15;73(2):490-5 - PubMed
  88. Int J Oncol. 2015 Jul;47(1):335-42 - PubMed
  89. Oncoimmunology. 2018 Aug 15;7(10):e1490856 - PubMed
  90. Nature. 1989 Jan 26;337(6205):331-7 - PubMed
  91. Int J Cancer. 2015 Feb 15;136(4):945-54 - PubMed
  92. Stem Cells Transl Med. 2013 Sep;2(9):655-66 - PubMed
  93. Mol Ther. 2010 Oct;18(10):1874-84 - PubMed
  94. Immunol Rev. 2008 Apr;222:277-86 - PubMed
  95. Urol Oncol. 2018 Oct;36(10):440-447 - PubMed
  96. Methods Enzymol. 2010;477:125-44 - PubMed
  97. Cancer Immunol Immunother. 2015 Jul;64(7):791-804 - PubMed
  98. Oncogene. 2008 Apr 10;27(17):2375-81 - PubMed
  99. Gene Ther. 2009 May;16(5):689-99 - PubMed
  100. J Virol. 2002 May;76(9):4612-20 - PubMed
  101. Int J Oncol. 2015 Aug;47(2):668-78 - PubMed
  102. Clin Cancer Res. 2017 Oct 1;23(19):5846-5857 - PubMed
  103. J Virol. 2012 Oct;86(19):10862-5 - PubMed
  104. Clin Cancer Res. 1996 Jan;2(1):53-7 - PubMed
  105. Clin Cancer Res. 2004 Nov 1;10(21):7199-206 - PubMed
  106. J Gen Virol. 2015 Sep;96(9):2734-2742 - PubMed
  107. J Natl Cancer Inst. 2013 Jul 3;105(13):968-77 - PubMed
  108. Oncolytic Virother. 2014;3:83-91 - PubMed
  109. Cancer Res. 2002 Jul 1;62(13):3812-8 - PubMed
  110. J Invest Dermatol. 2008 Apr;128(4):988-98 - PubMed
  111. J Virol. 2011 Mar;85(5):2201-11 - PubMed
  112. Clin Cancer Res. 1997 Nov;3(11):2081-8 - PubMed
  113. Anticancer Res. 2007 Jul-Aug;27(4B):2311-6 - PubMed
  114. Cancer Res. 2006 Mar 15;66(6):3230-7 - PubMed
  115. Prog Clin Biol Res. 1983;119:159-69 - PubMed
  116. Science. 2010 Aug 27;329(5995):1026-7 - PubMed
  117. Br J Cancer. 2009 Apr 7;100(7):1154-64 - PubMed
  118. J Cell Sci. 2020 Mar 6;133(5): - PubMed
  119. Nat Med. 2011 Jan;17(1):105-9 - PubMed
  120. Virus Res. 1994 Aug;33(2):179-98 - PubMed
  121. Nat Med. 2005 Oct;11(10):1073-81 - PubMed
  122. J Biol Chem. 2005 Jan 14;280(2):1474-81 - PubMed
  123. J Gene Med. 2007 Sep;9(9):764-78 - PubMed
  124. Semin Oncol. 2010 Oct;37(5):430-9 - PubMed
  125. Gene Ther. 2001 Aug;8(15):1123-31 - PubMed
  126. J Virol. 2018 Feb 26;92(6): - PubMed
  127. Nat Med. 2013 Apr;19(4):452-7 - PubMed
  128. Hum Gene Ther. 1997 Jan 1;8(1):73-85 - PubMed
  129. J Clin Oncol. 2018 May 10;36(14):1419-1427 - PubMed
  130. FEBS Lett. 2019 Dec;593(24):3609-3622 - PubMed
  131. Clin Cancer Res. 2016 Aug 1;22(15):3791-800 - PubMed
  132. Cancer Biother Radiopharm. 2010 Aug;25(4):487-95 - PubMed
  133. Hum Gene Ther. 2018 Feb;29(2):160-179 - PubMed
  134. Cancer Gene Ther. 2011 Apr;18(4):288-96 - PubMed
  135. Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188339 - PubMed
  136. J Virol. 2009 May;83(9):4565-73 - PubMed
  137. Curr Cancer Drug Targets. 2018;18(2):124-138 - PubMed
  138. J Immunother Cancer. 2016 Mar 15;4:17 - PubMed
  139. Mol Immunol. 2003 Sep;40(2-4):109-23 - PubMed
  140. Mol Ther. 2007 Sep;15(9):1600-6 - PubMed
  141. Mol Pharm. 2005 Nov-Dec;2(6):500-8 - PubMed
  142. Nat Rev Cancer. 2014 May;14(5):359-70 - PubMed
  143. Sci Transl Med. 2016 Mar 2;8(328):328rv4 - PubMed
  144. Gene Ther. 2017 Feb;24(2):92-103 - PubMed
  145. Nat Methods. 2009 May;6(5):343-5 - PubMed
  146. J Virol. 2003 Feb;77(4):2512-21 - PubMed
  147. Mol Ther. 2001 May;3(5 Pt 1):768-78 - PubMed
  148. Hum Gene Ther. 2007 Jan;18(1):51-62 - PubMed
  149. J Virol. 2005 Nov;79(22):14429-36 - PubMed
  150. Science. 1996 Dec 6;274(5293):1672-7 - PubMed
  151. Clin Cancer Res. 2017 Jan 1;23(1):239-249 - PubMed
  152. N Engl J Med. 2006 Feb 9;354(6):567-78 - PubMed
  153. Biochim Biophys Acta. 2002 May 3;1575(1-3):1-14 - PubMed
  154. PLoS One. 2008 Jun 18;3(6):e2409 - PubMed
  155. Cancer Res. 2010 Jun 1;70(11):4297-309 - PubMed
  156. Mol Pharm. 2011 Oct 3;8(5):1559-72 - PubMed
  157. J Clin Invest. 2004 Jul;114(1):67-76 - PubMed
  158. Cancer Cell. 2017 Oct 9;32(4):460-473.e6 - PubMed
  159. Clin Cancer Res. 2011 Nov 1;17(21):6712-22 - PubMed
  160. Mol Ther. 2013 Mar;21(3):620-8 - PubMed

Publication Types

Grant support